Background-Cardiovascular events occur among statin-treated patients, albeit at lower rates. Risk factors for this "residual risk" have not been studied comprehensively. We aimed to identify determinants of this risk above and beyond lipid-related risk factors. Methods and Results-A total of 9251 coronary patients with low-density lipoprotein cholesterol Ͻ130 mg/dL randomized to double-blind atorvastatin 10 or 80 mg/d in the Treating to New Targets (TNT) study had complete on-treatment 1-year lipid data. Median follow-up was 4.9 years. The primary end point was major cardiovascular events (nϭ729): coronary death, nonfatal myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. 
S
tatins are the most widely used lipid-lowering agents and the standard of care for individuals with or at high risk for cardiovascular disease. 1, 2 It is currently estimated that 1 of every 8 US adults is treated with lipid-lowering therapy, mostly statins. 3 This number is expected to increase because a large proportion of US adults remain untreated despite meeting guideline recommendations for therapy, including almost two thirds of individuals at high cardiovascular risk. 3 
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Current guidelines focus on low-density-lipoprotein (LDL) cholesterol lowering as the primary target of therapy, tailoring the level of optimal LDL cholesterol reduction to the individual's level of risk. 1 However, cardiovascular risk among statin-treated individuals remains high and has been called residual risk. Results from a meta-analysis of statin trials involving 90 056 individuals found that the rate of a major cardiovascular event (MCVE) occurring during 5 years of follow-up among statin-treated patients was 21 .7% (1 in 5) for individuals with prior cardiovascular disease and 9.5% (1 in 10) for those without prior disease. 4, 5 Even after low LDL cholesterol (70 -100 mg/dL) was achieved, residual risk was reduced but remained high in the Treating to New Targets (TNT) trial, with 8.7% of the group allocated to atorvastatin 80 mg experiencing a major event over a 5-year period. 6 Thus, factors other than LDL cholesterol lowering determine risk.
The mechanisms underlying this residual risk are uncertain. Identification of these factors is important for more effective tailoring of risk reduction strategies to match the individual level of risk and for development of new treatment targets. This analysis of the TNT study aimed to identify clinical determinants of residual risk by examining the effect of various clinical and lipid-related risk factors among patients with stable coronary disease treated to low LDL cholesterol targets. A secondary aim was to evaluate differences in residual risk according to high-versus low-dose statin therapy.
Methods

Study Population
The TNT design has previously been published. 6, 7 TNT was a multicenter clinical trial that randomized 10 001 men and women 35 to 75 years of age with stable coronary disease (previous myocardial infarction, previous or present angina with objective evidence of atherosclerotic coronary disease, or previous coronary revascularization procedure) in a parallel-group double-blinded treatment with atorvastatin 80 or 10 mg/d. 6, 7 At the screening visit, previously prescribed lipid-lowering drugs were discontinued for at least 6 weeks before an open-label 8-week run-in period with atorvastatin 10 mg daily. Patients with triglycerides Ͼ600 mg/dL (6.8 mmol/L) after discontinuation of previous lipid-lowering therapy were excluded. At the end of an open-label 8-week run-in period with atorvastatin 10 mg/d, patients with mean LDL cholesterol Ͻ130 mg/dL (3.4 mmol/L) were randomized to double-blind therapy with atorvastatin 80 or 10 mg/d. In addition to the inclusion and exclusion criteria of the TNT trial as previously published, 6 individuals were eligible for this analysis if they had complete 1-year lipid and apolipoprotein measurements and did not experience an MCVE or death in year 1, resulting in 9251 individuals for this analysis.
Assessment of Clinical and Laboratory Factors
At the screening visit, an informed consent was signed, demographic characteristics were assessed, vital signs were measured, all concomitant medications were documented, and a medical history was recorded. Metabolic syndrome was defined according to the National Cholesterol Education Program's Third Adult Treatment Panel definition. 8 A body mass index of 28 kg/m 2 was used instead of waist circumference, which was not assessed at screening.
Baseline and 1-year measurements were performed on fasting blood samples as previously described. 2, 9 All baseline measurements were performed on 10 mg atorvastatin at the end of an 8-week open-label run-in period. Concentrations of total cholesterol, highdensity-lipoprotein (HDL) cholesterol, and triglycerides were quantified by standard enzymatic techniques. LDL cholesterol was calculated with the Friedewald formula when triglycerides were Ͻ400 mg/dL. 10 For triglycerides Ն400 mg/dL, LDL cholesterol was measured by ultracentrifugation. Concentrations of apolipoprotein B and A-I were measured by immunonephelometry (Behring Nephelometer BNII, Marburg, Germany). 2, 9 Other laboratory measurements included white blood cells, uric acid, creatinine, blood urea nitrogen, and lactate dehydrogenase.
Assessment of Outcomes
Participants were followed up for a median of 4.9 years. The primary end point was a composite end point of MCVEs defined as coronary death, nonfatal myocardial infarction, resuscitated cardiac arrest, and fatal or nonfatal stroke. For this analysis, we also examined the expanded secondary end point of MCVEs plus death, documented angina, or arterial revascularization. An independent end-point committee adjudicated all potential end points in a blinded fashion.
Statistical Analyses
Summary statistics were calculated according to the occurrence of the primary or secondary end point. Candidate variables that could be related to residual risk were selected a priori on the basis of the literature and known risk factors. Statistical tests for outcomes were performed according to the intention-to-treat principle on all subjects who survived to year 1 without the end point occurring and who had complete year 1 lipid and apolipoprotein data. Year 1 was chosen because on-treatment lipids and apolipoproteins were part of the major predictor variables in the analysis and this was the first time point at which a complete panel of lipids and apolipoproteins was measured. The association of each of the candidate variables in relation to the risk of primary (or secondary) end point was assessed by univariable Cox proportional hazard models that calculated the hazard ratios, 95% confidence intervals, and 2 statistics. Then, also on an a priori basis, we grouped together a set of variables that are the traditional risk factors of age, sex, smoking, diabetes mellitus, and hypertension (family history was not obtained in TNT). We included this set of variables, together with randomized treatment assignment, in a single model and referred to this model as the basic model. Next, variables that were statistically significant at a value of PϽ0.10 from the univariable analysis were then entered into the multivariable model. With the use of an unbiased statistical method of forward stepwise regression, variables that met a critical value of PϽ0.05 were selected into the multivariable model.
We then conducted 2 sensitivity analyses. First, we performed the multivariable model after excluding baseline medication use other the randomization treatment assignment. Second, we expanded the basic model to include the on-treatment 1-year lipids and apolipoproteins to identify predictors that remained statistically significant independent of the achieved levels of on-treatment lipids and apolipoproteins.
Treatment-by-variable interactions were assessed by use of likelihood ratio 2 statistic and Wald P values to compare models with and without the interaction term. Interactions between the levels of on-treatment lipids and apolipoproteins with the multivariable predictors were also assessed.
Finally, we evaluated the multivariable model discrimination using the Harrell c index, which estimates the probability that, of 2 randomly chosen patients, the patient with the higher prognostic score will be more likely to be a case compared with the patient with the lower prognostic score. 11 Values of c index near 0.5 indicate that the prognostic score is no better than a coin flip, whereas values near 1.0 indicate that the model variables virtually always determine which patient has a better prognosis.
Results
During a median follow-up of 4.9 years, a total of 729 (7.8%) MCVE primary and 1870 secondary end points occurred after year 1. Table 1 shows the baseline characteristics for MCVE incident cases and noncases, which were similar to the overall TNT study population. 6 The prevalence of cardiovascular risk factors and prior cardiovascular disease was typical of a population with coronary disease, with a worse cardiovascular risk profile among cases compared with noncases. Similar results were found when cases were categorized according to the expanded secondary end point (results not shown).
Univariable Determinants of Risk
The primary end point of MCVE that occurred after year 1 was reduced with atorvastatin 80 versus 10 mg by 18% (Pϭ0.007; Table 2 ), similar to the overall TNT relative risk reduction of 22%. 6 Associations for each of the clinical risk factors and baseline and 1-year laboratory parameters in relation to the primary end point of MCVE were obtained from separate Cox regression models ( Table 2 ). Most of the clinical risk factors and all the baseline and 1-year lipids and apolipoproteins, in addition to baseline white blood cell count, glucose, uric acid, blood urea nitrogen, and lactate dehydrogenase, were statistically significantly associated with MCVEs. Similar associations were also noted in relation to the expanded secondary end point that BMI indicates body mass index; LDL, low-density lipoprotein; HDL, highdensity lipoprotein; and ACE, angiotensin-converting enzyme.
*The analysis includes only subjects who survived to the year 1 visit without a major cardiovascular event and with complete year 1 lipids data because year 1 lipids data were included in the analysis model as predictor variables in all subsequent analyses. included all-cause death, angina, and revascularization (data not shown).
Multivariable Determinants of Risk
With the use of forward stepwise regression, statistically significant variables were added to the basic model (randomization treatment, age, sex, smoking, diabetes mellitus, and hypertension). Multivariable determinants of increased risk (Table 3) were older age, increased body mass index, male sex, hypertension, diabetes mellitus, baseline apolipoprotein B and blood urea nitrogen, current smoking, prior cardiovascular disease, and calcium channel blocker use. Determinants of decreased risk were high-dose statin, aspirin use, and baseline apolipoprotein A-I. On-treatment 1-year levels of lipids and apolipoproteins were not selected into the multivariable model because they were not associated with risk after baseline apolipoproteins and clinical risk factors were taken into account. When we repeated the multivariable analysis in Table 3 for the secondary expanded end point, nearly identical results were obtained, except that both baseline apolipoprotein B and 1-year apolipoprotein B and A-I were also statistically significant (data not shown).
Sensitivity Analyses
We performed 2 additional sensitivity analyses. First, we repeated the multivariable analysis in Table 3 after excluding baseline concurrent medication use, obtaining very similar results (Table I in the online-only Data Supplement). Then, to determine whether the multivariable determinants remained associated with risk independently of the achieved levels of on-treatment 1-year lipids and apolipoproteins, we performed a second sensitivity analysis by expanding the basic model to include the 1-year lipids and apolipoproteins. None of the 1-year lipids or apolipoproteins was associated with risk of the primary or secondary end point.
Tests for Interactions
We tested for whether the randomization treatment of atorvastatin 80 versus 10 mg modified the association of the multivariable determinants of risk. Generally similar predictors of risk were seen among subjects allocated to atorvastatin 10 versus 80 mg (Table 4 ). There were no statistically significant interactions at a value of PϽ0.01.
Because individuals who achieve lower lipid targets on therapy still experience events, we determined whether the multivariable determinants differed among patients on the basis of their achieved levels of 1-year lipids and apolipoproteins. There were no statistically significant interactions at a value of PϽ0.01.
Prognostic Model Discrimination
Finally, we assessed the overall model discrimination for the multivariable model using the Harrell c index, 11 a generalization of the area under the receiver-operating characteristic curve. The multivariable model (Table 3) provided acceptable discrimination of cases from noncases with a c index of 0.679. A similar multivariable model that excluded baseline medication use (Table I in 
Discussion
In the TNT trial of secondary prevention patients with low LDL cholesterol and triglycerides Ͻ600 mg/dL, residual risk was multifactorial and related to baseline lipid-related and nonlipid risk factors, including baseline apolipoproteins, increased body mass index, smoking, hypertension, and diabetes mellitus. Generally similar determinants of risk were identified among subjects allocated to high-versus low-dose statin therapy. Known baseline clinical and lipid-related variables performed moderately well in discriminating cases from noncases. Thus, a multifaceted secondary prevention approach emphasizing modifiable traditional risk factors should be underscored to reduce residual risk.
It is commonly believed that residual risk on statin treatment is related to the achieved levels of HDL cholesterol or triglycerides, in addition to achieved LDL cholesterol. 12 At first glance, the findings of this TNT analysis may seem discordant with the results of a prior TNT analysis that found an inverse association of HDL cholesterol with MCVEs. 13 But in the prior analysis, there was no association between HDL cholesterol and MCVEs (Pϭ0.45) after adjustment for baseline apolipoproteins. 13 The present study also found univariable associations for HDL cholesterol and triglycerides with risk that became nonstatistically significant in multivariable models that additionally adjusted for baseline apolipoproteins and other risk factors. In contrast, among primary prevention patients with low LDL cholesterol but elevated C-reactive protein in the Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, neither on-treatment HDL cholesterol nor triglycerides were associated with residual risk, even without adjustment for apolipoproteins. 14, 15 The JUPITER study population differed from TNT in being a primary prevention nondiabetic population recruited on the basis of chronic inflammation, and these differences in the study populations may contribute to differences in prognostic markers. However, several other trials also did not find statistically significant associations for on-treatment HDL cholesterol or triglycerides with residual risk among the active or more intensely treated arms. 16 -18 There are limited prior data evaluating the magnitude of residual risk that is explained by clinical risk factors. However, 2 prior studies from hypercholesterolemic primary prevention populations identified risk factors for residual risk similar to those found in the current TNT study of secondary prevention. In a previous study from the West of Scotland Coronary Prevention Study (WOSCOPS), which included only middle-aged hypercholesterolemic men without prior myocardial infarction, important predictors of risk included older age, smoking, blood pressure, diabetes mellitus, and baseline ratio of total to HDL cholesterol, and a 5-year risk score for residual risk was modeled. 19, 20 In a subsequent analysis from hypercholesterolemic asymptomatic men and women from the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study, the risk factors for incident coronary events were male sex, older age, diabetes mellitus, hypertension, smoking, low baseline HDL cholesterol, and increased body mass index (women only). 21 Furthermore, the present findings do not support the routine remeasurement of on-treatment 1-year lipids or apolipoproteins once a baseline measurement has been obtained on statin therapy because 1-year levels were not related to residual risk above and beyond the initial (on-treatment) values and clinical risk factors. A prior TNT analysis found positive associations for on-treatment apolipoproteins and non-HDL cholesterol with residual risk in minimally adjusted models (age and sex adjusted). 2 The present study extends the prior findings by demonstrating that once additional clinical risk factors and baseline levels of apolipoproteins are included in more comprehensive multivariable models, there is no independent association for 1-year on-treatment levels of apolipoproteins with residual risk. Notably, in both MEGA and WOSCOPS, on-treatment lipid values were not associated with risk in multivariable models. 20, 21 Risk factors for CVD often cluster so that individuals with dyslipidemia may also have a number of cardiovascular risk factors. 22, 23 Even after low LDL cholesterol levels are achieved, as in TNT, a greater duration and/or burden of atherosclerotic disease are often present among coronary patients that increase their residual risk. For example, the increased risk associated with calcium channel blocker use is at least in part related to "confounding by indication" because patients taking calcium channel blockers at baseline probably had a higher burden (severity and/or frequency) of angina. For the rest of the multivariable determinants of risk, we believe that our results show the expected (and not paradoxical) relationships of established risk factors with clinical outcomes in the secondary prevention setting because of better assessment of potential confounders in the TNT trial and less differential surveillance bias. Detailed risk factor data and information about potential confounders were well assessed in the TNT clinical trial; hence, the results are less prone to the confounder bias that may be seen in other prospective studies that did not account sufficiently for potential confounders and that likely resulted in the "paradox phenomenon." 24 We also believe that there was less differential surveillance bias in the TNT study because it was a randomized, double-blinded clinical trial compared with unblinded prospective studies that may be more prone to this type of bias.
The multivariable model that included these clinical risk factors, concurrent medication use, and prior cardiovascular history resulted in acceptable discrimination of future cases and noncases. Studies are needed to identify additional factors that may contribute to residual risk and to test the comparative effectiveness of treatment strategies that simultaneously target multiple risk factors.
The present study has potential limitations and several strengths. TNT excluded patients with LDL cholesterol Ͼ130 mg/dL on atorvastatin 10 mg or untreated triglycerides Ͼ600 mg/dL. This prospective analysis, although conducted within a clinical trial, was observational and may be subject to bias because individuals who become cases may differ from noncases in unmeasured ways. Although we examined clinical and traditional risk factor data, novel risk factor data were not available for the entire TNT population for analysis. However, a prior case-control study found little association for a selected group of nonlipid biomarkers with residual risk. 25 Finally, it is unclear whether our results would be applicable to other individuals from primary or secondary prevention who were excluded from the trial.
Strengths of the study are the large number of individuals with baseline and 1-year lipids and apolipoproteins and the detailed information on clinical risk factors. To the best of our knowledge, this is the first analysis of the role of clinical risk factors in a secondary prevention study, in particular one in which baseline LDL cholesterol was low and the achieved LDL cholesterol was even lower with half the study population allocated to potent statin therapy. Finally, because the TNT study design tested a low-and high-dose statin in a randomized fashion, we were able to take advantage of this *Hazard ratio, 95% confidence intervals (CIs), and P values are based on multivariable Cox proportional hazard analysis including all specified variables in the model. Hazard ratios and the corresponding 95% CIs are calculated on the basis of a 1-SD increase for the continuous variables.
†The P values for the interaction terms between treatment and the corresponding variables are based on the Wald test of the corresponding interaction terms in the multivariable model listed above.
clinical trial design using the intention-to-treat analysis to test for treatment-by-variable interactions.
Conclusions
The key finding from this study is that residual risk among statin-allocated coronary patients was multifactorial and related to baseline lipid-related and nonlipid risk factors, including baseline apolipoproteins, increased body mass index, smoking, hypertension, and diabetes mellitus. Known baseline clinical and lipid-related variables performed moderately well in discriminating future cases from noncases. Thus, a multifaceted secondary prevention approach targeting modifiable risk factors should be underscored as the cornerstone of optimal cardiovascular risk assessment and prevention.
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